Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cells

Endocrinology

Volumn 144, Issue 8, 2003, Pages 3423-3432

  Spitzweg, Christine ^a   Scholz, I V ^a   Bergert, E R ^b   Tindall, D J ^b   Young, C Y F ^b   Goke B ^a   Morris, J C ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; IODINE 131; MESSENGER RNA; MIBOLERONE; PLASMID VECTOR; PROSTATE SPECIFIC ANTIGEN; RETINOIC ACID; RETINOIC ACID RECEPTOR; SODIUM IODIDE SYMPORTER;

ARTICLE; CANCER CELL CULTURE; CELL KILLING; CELL TRANSPORT; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; GENE ACTIVITY; GENE CONTROL; GENE DELIVERY SYSTEM; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; WESTERN BLOTTING;

EID: 0041814617     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2002-0206     Document Type: Article

References (55)

1. Mazzaferri EL 1996 Carcinoma of follicular epithelium: Radioiodine and other treatments and outcomes. In: Braverman LE, Utiger RD, eds. The thyroid: a fundamental and clinical text. 7th ed. Philadelphia: Lippincott-Raven; 922-945
2. Dai G, Levy O, Carrasco N 1996 Cloning and characterization of the thyroid iodide transporter. Nature 379:458-460
3. Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, Jhiang SM 1996 Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 226:339-345
4. Smanik PA, Ryu K-Y, Theil KS, Mazzaferri EL, Jhiang SM 1997 Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 138:3555-3558
5. Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC 2001 The sodium iodide symporter and its potential in cancer therapy. J Clin Endocrinol Metab 86:3327-3335
6. Hart IR 1996 Tissue specific promoters in targeting systemically delivered gene therapy. Semin Oncol 23:154-158
7. Stearns ME, McGarvey T 1992 Prostate cancer: therapeutics, diagnostics, and basic studies. Lab Invest 67:540-552
8. Dannull J, Belldegrun AS 1997 Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen. Br J Urol 79:97-103
9. Hrouda D, Dalgleish AG 1996 Gene therapy for prostate cancer. Gene Ther 3:845-852
10. Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK, Frelinger JG 1997 Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc Natl Acad Sci USA 94:6369-6374
11. Cleutjens KBJM, van der Korput HAGM, Ehren-van-Eekelen CC, Sikes RA, Fasciana C, Chung LW, Trapman J 1997 A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol Endocrinol 11:1256-1265
12. Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Tindall DJ, Young CYF, Morris JC 1999 Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 59:2136-2141
13. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CYF, Morris JC 2000 Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 60:6526-6530
14. Spitzweg C, Dietz AB, O'Connor MK, Bergert ER, Tindall DJ, Young CYF, Morris JC 2001 In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 8:1524-1531
15. Evans TR, Kaye SB 1999 Retinoids: present role and future potential. Br J Cancer 80:1-8
16. Kogai T, Schultz J, Johnson L, Huang M, Brent G 2000 Retinoic acid induces sodium/iodide symporter gene expression and radioiodine uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci USA 97:8519-8524
17. Schmutzler C, Winzer R, Meissner-Weigl J, Kohrle J 1997 Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 240:832-838
18. Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K, Goretzki PE, Roeher HD 1998 Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and paillary carcinoma. World J Surg 22:569-574
19. Koshiuka K, Elstner E, Williamson E, Said JW, Tada Y, Koeffler HP 2000 Novel therapeutic approach: organic arsenical (melarsoprol) alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo. Br J Cancer 82:452-458
20. Nehme A, Varadarajan P, Sellakumar G, Gerhold M, Niedner H, Zhang Q, Lin X, Christen RD 2001 Modulation of docetaxel-induced apoptosis and cell cycle arrest by all-trans-retinoic acid in prostate cancer cells. Br J Cancer 84:1571-1576
21. Zhao XY, Ly LH, Peehl DM, Feldman D 1999 Induction of androgen receptor by 1α, 25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 140:1205-1212
22. Fong C-J, Sutkowski DM, Braun EJ, Bauer KD, Sherwood ER, Lee C, Kozlowski JM 1993 Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells. J Urol 149:1190-1194
23. Esquenet M, Swinnen JV, Heyns W, Verhoeven G 1996 Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1α, 25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate 28:182-194
24. Weiss SJ, Philip NJ, Grollmann EF 1984 Iodine transport in a continuous line of cultured cells from rat thyroid. Endocrinology 114:1090-1098
25. Urabe M, Hershman JM, Pang X-P, Murakami S, Sugawara M 1991 Effect of lithium on function and growth of thyroid cells in vitro. Endocrinology 129:807-814
26. - symport activity is present in membrane vesicles from thyrotropin-deprived non-I-transporting cultured thyroid cells. Proc Natl Acad Sci USA 91:3789-3793
27. Castro MR, Bergert ER, Beito TG, Roche PC, Ziesmer SC, Jhiang SM, Goellner JR, Morris JC 1999 Monoclonal antibodies against the human sodium iodide symporter: utility for immunocytochemistry of thyroid cancer. J Endocrinol 163:495-504
28. Chomczynski P, Sacchi N 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159
29. Spitzweg C, Joba W, Eisenmenger W, Heufelder AE 1998 Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab 83:1746-1751
30. Mandell RB, Mandell LZ, Link CJ 1999 Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 59:661-668
31. Carrasco N 1993 Iodide transport in the thyroid gland. Biochem Biophys Acta 1154:65-82
32. - symporter gene. Endocrinology 138:4493-4496
33. Cho J-Y, Xing S, Liu X, Buckwalter TLF, Hwa L, Sferra TJ, Chiu I-M, Jhiang SM 2000 Expression and activity of human Na+/I- symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Ther 7:740-749
34. Boland A, Ricard M, Opolon P, Bidart J-M, Yeh P, Filetti S, Schlumberger M, Perricaudet M 2000 Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 60:3484-3492
35. Smit JWA, Schröder-van der Elst JP, Karperien M, Que I, van der Pluijm G, Goslings B, Romijn JA, van der Heide D 2000 Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. Thyroid 10:939-943
36. Smit JW, Schroder-Van der Elst JP, Karperien M, Que I, Stokkel M, van der Heide D, Romijn JA 2002 Iodide kinetics and experimental (131)I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line. J Clin Endocrinol Metab 87:1247-1253
37. - symporters for radioiodide concentrator gene therapy. J Nucl Med 41:1898-1904
38. Carlin S, Cunningham SH, Boyd M, McCluskey AG, Mairs RJ 2000 Exper-imental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: effect on clonogenicity in both two- and three-dimensional models. Cancer Gene Ther 7:1529-1536
39. Haberkom U, Henze M, Altmann A, Jiang S, Morr I, Mahmut M, Peschke P, Kubler W, Debus J, Eisenhut M 2001 Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med 42:317-325
40. La Perle KMD, Shen D, Buckwalter TLF, Williams B, Haynam A, Hinkle G, Pozderac R, Capen CC, Jhiang SM 2001 In vivo expression and function of the sodium iodide symporter following gene transfer in the MATLyLu rat model of metastatic prostate cancer. Prostate 50:170-178
41. Blutt SE, Allegretto EA, Pike JW, Weigel NL 1997 1, 25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cell in G1. Endocrinology 138:1491-1497
42. Peehl DM, Wong ST, Stamey TA 1993 Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells. Prostate 23:69-78
43. Willett WC, Hunter DJ 1994 Vitamin A and cancers of the breast, large bowel, and prostate: epidemiologic evidence. Nutr Rev 52:S53-S59
44. Reichman ME, Hayes RB, Ziegler RG, Schatzkin A, Taylor PR, Kahle LL, Fraumeni JF 1990 Serum vitamin A, and subsequent development of prostate cancer in the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Cancer Res 50:2311-2315
45. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP 1983 LNCaP model of human prostatic carcinoma. Cancer Res 43:1809-1818
46. Berns EM, de Boer W, Mulder E 1986 Androgen-dependent growth regulation of and release of specific protein(s) by the androgen-receptor containing human prostate tumor cell line LNCaP. Prostate 9:247-259
47. Montgomery BT, Young CYF, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, Tindall DJ 1992 Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate 21:63-73
48. Dahiya R, Zhang DY, Ho RJ, Haughney PC, Hayward SW, Cunha GR, Narayan P 1995 Regression of LNCaP human prostate tumor xenografts in arhymic nude mice by 13-cis-retinoic acid and androgen ablation. Biochem Mol Biol Int 35:487-498
49. Allegretto EA, McClurg MR, Lazarchik SB, Clemm DL, Kerner SA, Elgort MG, Boehm MF, White SK, Pike JW, Heyman RA 1993 Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effects of metabolism. J Biol Chem 268:26625-26633
50. Giguere V 1994 Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. Endocr Rev 15:61-79
51. Young CYF, Murtha PE, Andrews PE, Lindzey JK, Tindall DJ 1994 Antagonism of androgen action in prostate tumor cells by retinoic acid. Prostate 25:39-45
52. Dahiya R, Park HD, Cusick J, Vessella RL, Fournier G, Narayan P 1994 Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int J Cancer 59:126-132
53. Esquenet M, Swinnen JV, Heyns W, Verhoeven G 1997 LNCaP prostatic adenocarcinoma cells derived from low and high passage numbers display divergent responses not only to androgens but also retinoids. J Steroid Biochem Mol Biol 62:391-399
54. Huang HFS, Li MT, Irwin RJ, Androgen and retinoic acid regulation of retinoic acid receptor (RAR) mRNA in the LNCaP cells and its relationship with cell growth. International Symposium on Biology of Prostate Growth, Washington, DC, 1996, p 80
55. Fowler JE, Whitmore WF 1981 The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 126:372-375